Dendreon: Targeting Cancer, Transforming Lives
Home   |   Site Map   |   Contact Us   
 Search
 

    Print Print page     Email Email page

SITE MAP

ABOUT US
  • Letter From the President and CEO
  • Our Commitment to Patients
  • Mission and Values
    • Corporate Responsibility
    • Corporate Compliance
  • Executive Leadership Team
    • Mitchell H. Gold, M.D.
    • Hans E. Bishop
    • Mark W. Frohlich, M.D.
    • Richard F. Hamm, Jr.
    • Richard J. Ranieri
    • Gregory T. Schiffman
    • David L. Urdal, Ph.D.
  • Board of Directors
    • Richard B. Brewer
    • Susan B. Bayh
    • Gerardo Canet
    • Ian T. Clark
    • Bogdan Dziurzynski, D.P.A.
    • Mitchell H. Gold, M.D.
    • Pedro Granadillo
    • David L. Urdal, Ph.D.
    • Douglas G. Watson
  • Contact Us
  • Directions
PRODUCTS
  • PROVENGE
    • Manufacturing
    • Scientific Publications
PATIENT RESOURCES
  • Patient Access
  • Clinical Trials
  • Patient Information
RESEARCH AND DEVELOPMENT
  • Pipeline
  • Sipuleucel-T
  • Lapuleucel-T
  • TRPM8
  • Preclinical Programs
INVESTORS AND NEWSROOM
  • Governance
  • Stock Quote
  • Press Releases
  • Webcasts and Presentations
  • SEC Filings
  • Analyst Coverage
  • Annual Reports
  • Information Requests
  • Email Alerts
  • Investor Tools box
    • RSS Feeds
    • Email Alerts
    • IR Contacts
    • Financial Tear Sheet
CAREERS
  • Career Opportunities
  • Working at Dendreon
  • Your Benefits
Privacy Policy  |  Legal Notice  |  Terms of Use
© 2010 Dendreon Corporation. All Rights Reserved.

P-A-04.10-008.00